TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02465723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI with IVIM DW-MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
Study: NCT02364115

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Study: NCT02480439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648 Tablet
Description: Tak-648 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648 Tablet
Description: Tak-648 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648 Tablet
Description: Tak-648 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648 Oral Solution
Description: TAK-648 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648 Oral Solution
Description: TAK-648 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648 Oral Solution
Description: TAK-648 oral solution
Study: NCT02268084

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic EEG/ECG-guided Resonance Therapy
Description: A coil delivers a pulsed magnetic field to the cortex of the brain

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
Study: NCT04173481

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Group
Description: Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
Study: NCT02095574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]ABT-199 (GDC-0199)
Description: \[14C\]ABT-199 will be administered as a single oral administration
Study: NCT00552916

Intervention type: DEVICE
Group type: OTHER
Intervention: Compex Motion Stimulator
Description: 'True' Functional Electrical Stimulation Assisted Walking

Intervention type: DEVICE
Group type: OTHER
Intervention: Compex Motion Stimulator
Description: 'False' FES
Study: NCT03415217

Intervention type: OTHER
Group type: OTHER
Intervention: Neighbourhood Team Development Program
Description: The Neighbourhood Team Development Program aims to both enhance team development and resident centredness in LTC. The Program has three components, designed to modify the physical environment, the organization and delivery of services, and the alignment of staff members, to function independently and collaboratively in providing resident-centred care.
Study: NCT03817307

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI
Description: The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.
Study: NCT04572932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactobacillus delbruekii
Description: Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactobacillus delbruekii
Description: Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
Study: NCT01649661

Intervention type: BEHAVIORAL
Intervention: questionnaire

Intervention type: BEHAVIORAL
Intervention: questionnaire
Study: NCT04556695

Intervention type: OTHER
Intervention: Questionnaire survey
Description: Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)

Intervention type: OTHER
Intervention: Questionnaire survey
Description: Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)

Intervention type: OTHER
Intervention: Questionnaire survey
Description: Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)

Intervention type: DEVICE
Intervention: Accelerometer study
Description: Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.

Intervention type: DEVICE
Intervention: Accelerometer study
Description: Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.

Intervention type: OTHER
Intervention: Semi-structured interview study
Description: Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
Study: NCT02769455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference intakes
Description: FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.~The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-CNL
Description: The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.~The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant.
Study: NCT02837575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-HB01
Description: Investigational Product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate-buffered saline
Description: Placebo
Study: NCT03608592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord derived mesenchymal stem cells (UCMSCs) suspension
Description: Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: normal saline
Description: A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
Study: NCT02356068

Intervention type: OTHER
Intervention: ROTEM analysis
Description: 3 blood samples for ROTEM analysis
Study: NCT01931852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Participants in the CMR-guided care group will receive a cardiac MRI.
Study: NCT02289118

Intervention type: DRUG
Intervention: [18F]-T807 imaging tracer
Description: Tau Imaging tracer
Study: NCT01931852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACC/AHA Guideline adherent care
Description: Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
Study: NCT03659812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MACS technique
Description: MACS is a technique that allow us to tag and detect apoptotic spermatozoa. These apoptotic spermatozoa have phosphatidylserine in their membranes, so we add magnetic beads with Annexin V, which binds specifically to phosphatidylserine. The spermatozoa are then tagged and can be retained in a magnetic field, allowing us to collect just the non-apoptotic spermatozoa.
Study: NCT01382823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser
Description: Using the Femtosecond Laser to make a clear corneal incision.
Study: NCT02611557

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manual lymphatic drainage therapy
Description: Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
Study: NCT03922711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsule
Study: NCT05229575

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT
Study: NCT02231723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: Administered continuously twice daily with doses separated by 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: Administered continuously twice daily with doses separated by 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: Administered continuously twice daily with doses separated by 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: Administered continuously twice daily with doses separated by 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Arm B: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Arm B: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Study: NCT00612209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Treatment with ARQ 197
Study: NCT02231723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: MM-398 70 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Study: NCT01233440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX Albumin Fusion Protein
Description: Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX Albumin Fusion Protein
Description: Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX Albumin Fusion Protein
Description: Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma derived FIX [pdFIX]
Description: Single dose of 50 IU/kg of reference product, given as intravenous infusion
Study: NCT04006574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Core stabilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Core stabilization
Study: NCT04675645

Intervention type: OTHER
Group type: OTHER
Intervention: HU-Go app
Description: A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
Study: NCT03648268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation
Study: NCT03870893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hippotherapy
Description: 16weeks hippotherapy program
Study: NCT04547491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPI - hypotension prediction index
Description: treatment of hypotension before the appearance following HPI algorithm

Intervention type: DEVICE
Group type: OTHER
Intervention: GDT
Description: cardiac optimization and treatment of hypotension following standard clinical practice
Study: NCT00826540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT04372979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transfusion of SARS-CoV-2 Convalescent Plasma.
Description: 2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
Study: NCT03648268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation
Study: NCT00582972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg po qAM one-half hour before breakfast for 30 days
Study: NCT02564705

Intervention type: PROCEDURE
Intervention: Anterior Lumbar Interbody Fusion (ALIF)

Intervention type: PROCEDURE
Intervention: Posterior Fusion
Description: * Posterolateral Fusion (PLF)~* Posterior Lumbar Interbody Fusion (PLIF)~* Transforaminal Lumbar Interbody Fusion (TLIF)
Study: NCT01940107

Intervention type: OTHER
Group type: OTHER
Intervention: evaluations
Description: Only evaluations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol of physiotherapy exercises
Description: Oriented domiciliary physiotherapeutic exercises
Study: NCT02551237

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 50 Gy
Description: radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 25 Gy
Description: radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
Study: NCT02423642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy with regional citrate anticoagulation
Description: CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy with no anticoagulation or heparin
Description: CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
Study: NCT02144597

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquid formula low-calorie diet (LCD)
Description: The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquid formula low-calorie diet (LCD)
Description: The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Description: Participant went through Roux-en-Y gastric bypass (RYGB) surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y gastric bypass (RYGB)
Description: Participant went through Roux-en-Y gastric bypass (RYGB) surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Control diet
Study: NCT04372979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion of standard Plasma.
Description: 2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
Study: NCT05265585

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound - Cardiac Acquisition
Description: The evaluation of the algorithm takes place on patients with an indication for echocardiography.~This examination is done in a standard way with the potential specific explorations related to the indication of the examination. During the echocardiography, the operator records the search phase for the following reference views:~* Parasternal window (Parasternal long axis, Parasternal minor axis)~* Apical window (Apical 4 cavities, Apical 3 cavities, Apical 2 cavities~* Sub costal window, Sub costal 4 cavities, Inferior vena cava)
Study: NCT03623204

Intervention type: OTHER
Intervention: Dyspnea evaluation
Study: NCT02709941

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle strength training
Description: Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo